Germany: FSN Capital Partners acquires majority stake in Adragos Pharma Group

Nicolai Norrbom, principal, FSN Capital

Northern European PE firm, FSN Capital (FSNC), through Fund VI, has acquired a majority holding in B2B CDMO for pharmaceuticals company, Adragos Pharma Group. The current owner, Prange Group, remains invested. FSNC and Prange plan to support Adragos’ efforts to attain a leading global position in the highly attractive and well-protected pharmaceutical CDMO market. Details…

You must be a HMI Subscriber to view this content.

Subscribe Now »